Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDlasta versus PDgrastim in breast cancer patients receiving dose-dense AC-T chemotherapy
IRCT20190504043465N1Phase 3Completed
- Sponsor
- Pooyesh Darou
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegfilgrastim and PDgrastim in breast cancer (2 arms), sponsored by Pooyesh Darou. Primary endpoints: Change in absolute neutrophil count and Frequency of adverse effects. Started Oct 2016; status: completed.
02
Drugs
pegfilgrastimPDgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20190504043465N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190504043465N1.